Rampart Investment Management Company LLC lowered its holdings in Allergan plc (NYSE:AGN) by 7.0% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 5,144 shares of the company’s stock after selling 385 shares during the quarter. Rampart Investment Management Company LLC’s holdings in Allergan were worth $861,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the business. Cornerstone Advisors Inc. raised its holdings in shares of Allergan by 78.4% during the 1st quarter. Cornerstone Advisors Inc. now owns 430 shares of the company’s stock valued at $63,000 after buying an additional 189 shares in the last quarter. Cetera Advisor Networks LLC increased its stake in Allergan by 19.1% in the 1st quarter. Cetera Advisor Networks LLC now owns 2,552 shares of the company’s stock worth $373,000 after purchasing an additional 410 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in Allergan by 5.8% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 43,696 shares of the company’s stock worth $6,398,000 after purchasing an additional 2,396 shares during the period. Mid Atlantic Financial Management Inc. ADV purchased a new position in Allergan in the 1st quarter worth approximately $209,000. Finally, Keybank National Association OH increased its stake in Allergan by 58.5% in the 1st quarter. Keybank National Association OH now owns 4,991 shares of the company’s stock worth $731,000 after purchasing an additional 1,842 shares during the period. 80.45% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have commented on the company. JPMorgan Chase & Co. set a $200.00 price target on Allergan and gave the stock a “buy” rating in a research note on Wednesday, June 19th. UBS Group lifted their price target on Allergan from $172.00 to $189.00 and gave the stock a “buy” rating in a research note on Thursday, September 12th. Raymond James cut Allergan from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 25th. Barclays lifted their price target on Allergan from $176.00 to $188.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald lifted their price target on Allergan from $125.00 to $165.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $178.75.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $4.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.34 by $0.04. The firm had revenue of $4.09 billion for the quarter, compared to analyst estimates of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same period last year, the company earned $4.42 EPS. As a group, equities research analysts forecast that Allergan plc will post 16.69 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 13th. Stockholders of record on Tuesday, August 13th were given a $0.74 dividend. The ex-dividend date was Monday, August 12th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.78%. Allergan’s dividend payout ratio is currently 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: What is insider trading?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.